Braden Parker - Orchard Therapeutics Chief Officer
| ORTXDelisted Stock | USD 5.27 0.01 0.19% |
Insider
Braden Parker is Chief Officer of Orchard Therapeutics PLC
| Phone | 44 20 3 808 8286 |
| Web | https://www.orchard-tx.com |
Orchard Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2923) % which means that it has lost $0.2923 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7151) %, meaning that it created substantial loss on money invested by shareholders. Orchard Therapeutics' management efficiency ratios could be used to measure how well Orchard Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Orchard Therapeutics PLC currently holds 58.09 M in liabilities with Debt to Equity (D/E) ratio of 0.41, which is about average as compared to similar companies. Orchard Therapeutics PLC has a current ratio of 4.16, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Orchard Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| Prof MD | Hookipa Pharma | 80 | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| Janetta Trochimiuk | PDS Biotechnology Corp | 61 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Siew MS | Acumen Pharmaceuticals | N/A | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| James MBA | Amylyx Pharmaceuticals | 57 | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Gina Mazzariello | Amylyx Pharmaceuticals | 53 | |
| MSc MBA | Inozyme Pharma | 52 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| MBA MBA | Inozyme Pharma | 65 | |
| Christine MBA | Hookipa Pharma | 59 | |
Management Performance
| Return On Equity | -0.72 | |||
| Return On Asset | -0.29 |
Orchard Therapeutics PLC Leadership Team
Elected by the shareholders, the Orchard Therapeutics' board of directors comprises two types of representatives: Orchard Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orchard. The board's role is to monitor Orchard Therapeutics' management team and ensure that shareholders' interests are well served. Orchard Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orchard Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fulvio Mavilio, Chief Officer | ||
| Frank Thomas, Pres COO | ||
| Bobby MD, Member CEO | ||
| Benjamin Navon, Director Communications | ||
| John Cerio, Chief Officer | ||
| Braden Parker, Chief Officer | ||
| Nicoletta Loggia, Chief Officer | ||
| Renee Leck, Director Relations | ||
| Robin Kenselaar, VP Operations | ||
| Leslie Meltzer, Chief Officer |
Orchard Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orchard Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.72 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (3.43) % | |||
| Current Valuation | 302.52 M | |||
| Shares Outstanding | 22.76 M | |||
| Shares Owned By Insiders | 12.20 % | |||
| Shares Owned By Institutions | 87.80 % | |||
| Number Of Shares Shorted | 27.2 K | |||
| Price To Earning | (8.06) X | |||
| Price To Book | 4.74 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Orchard Stock
If you are still planning to invest in Orchard Therapeutics PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orchard Therapeutics' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |